A Study of LY4257496 in Participants With Cancer (OMNIRAY)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór złośliwy (zaawansowany, nieusuwalny lub z przerzutami)
- •Widoczne zmiany w badaniach tomografii/rezonansu magnetycznego
- •Nowotwór z dodatnią ekspresją białka GRPR
- •Jeden z następujących typów raka: rak piersi, przełyku, żołądka, jelita grubego, prostaty, macicy, jajnika lub inny nowotwór poza mózgiem
- •Dla raka piersi: potwierdzony status receptora estrogenowego i HER2
- •Ogólny stan zdrowia pozwalający na aktywne uczestnictwo w badaniu (skala ECOG ≤1)
- •Zdolność do regularnych wizyt kontrolnych i badań laboratoryjnych
✗ Disqualifies
- •Wcześniejsze leczenie radioaktywne (z wyjątkiem niektórych procedur u pacjentów z rakiem prostaty)
- •Zapalenie trzustki w ciągu ostatniego roku
- •Wcześniejsza radioterapia obejmująca ponad 25% szpiku kostnego
- •Wysoka akumulacja radioaktywności w całym szkielecie
- •Nieuleczona niedrożność moczowodu lub niekontrolowana inkontynencja
- •Aktywne zapalenie wątroby typu B
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (31)
City of Hope
Duarte, United States
University of California, Los Angeles (UCLA)
Santa Monica, United States
Stanford University Medical Center
Stanford, United States
Biogenix Molecular, LLC
Miami, United States
Moffitt
Tampa, United States
Emory University School of Medicine - Winship Cancer Institute
Atlanta, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
Barbara Ann Karmanos Cancer Institute
Detroit, United States
BAMF Health Inc.
Grand Rapids, United States
Washington University
St Louis, United States
New York University (NYU) Langone Medical Center
New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
University of Pittsburgh Medical Center
Pittsburgh, United States
Texas Oncology - DFW (Sammons CC)
Dallas, United States
MD Anderson Cancer Center
Houston, United States
Juravinski Cancer Centre
Hamilton, Canada
Lady Davis Institute for Medical Research Jewish General Hospital
Montreal, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
Princess Margaret Hospital
Toronto, Canada
Peking Union Medical College Hospital of Chinese Academy of Medical Sciences
Beijing, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Institut Curie
Paris, France
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France
Universitaetsklinikum Erlangen
Erlangen, Germany
Universitaetsklinikum Essen
Essen, Germany
LMU Klinikum Muenchen-Campus Grosshadern
München, Germany
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
München, Germany
National Cancer Center Hospital East
Chiba, Japan
Kyoto University Hospital
Kyoto, Japan
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Spain
Trial contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Physicians interested in becoming principal investigators please contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.